• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:先天性重排急性淋巴细胞白血病新生儿中罕见基因融合的鉴定。

Case Report: Rare Gene Fusions Identified in Neonate with Congenital -Rearranged Acute Lymphoblastic Leukemia.

机构信息

Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, SA 5000, Australia.

Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia.

出版信息

Genes (Basel). 2023 Jan 19;14(2):264. doi: 10.3390/genes14020264.

DOI:10.3390/genes14020264
PMID:36833191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9956107/
Abstract

Chromosomal rearrangements involving the gene occur frequently in acute lymphoblastic leukaemia (ALL). -rearranged ALL ( ALL) has poor long-term survival rates and is the most common ALL subtype in infants less than 1 year of age. ALL frequently occurs with additional chromosomal abnormalities including disruption of the gene, usually by exon deletion. Typically, ALL in infants is accompanied by a limited number of cooperative le-sions. Here we report a case of aggressive infant ALL harbouring additional rare gene fusions. Comprehensive genomic and transcriptomic analyses were performed on sequential samples. This report highlights the genomic complexity of this particular disease and describes the novel gene fusions and .

摘要

涉及 基因的染色体重排在急性淋巴细胞白血病(ALL)中经常发生。-重排 ALL(ALL)的长期生存率较差,是 1 岁以下婴儿中最常见的 ALL 亚型。ALL 常伴有其他染色体异常,包括 基因的破坏,通常通过外显子缺失。通常,婴儿的 ALL 伴有数量有限的协同性病变。我们在此报告一例伴有额外罕见 基因融合的侵袭性婴儿 ALL。对连续样本进行了全面的基因组和转录组分析。本报告强调了该疾病的基因组复杂性,并描述了新的基因融合 和 。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/782e229655e9/genes-14-00264-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/723ba22b2643/genes-14-00264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/bfa55c930c1f/genes-14-00264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/782e229655e9/genes-14-00264-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/723ba22b2643/genes-14-00264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/bfa55c930c1f/genes-14-00264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7b81/9956107/782e229655e9/genes-14-00264-g003.jpg

相似文献

1
Case Report: Rare Gene Fusions Identified in Neonate with Congenital -Rearranged Acute Lymphoblastic Leukemia.病例报告:先天性重排急性淋巴细胞白血病新生儿中罕见基因融合的鉴定。
Genes (Basel). 2023 Jan 19;14(2):264. doi: 10.3390/genes14020264.
2
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.KMT2A 重排急性淋巴细胞白血病:揭示这种高危疾病的基因组复杂性和异质性。
Cancer Lett. 2020 Jan 28;469:410-418. doi: 10.1016/j.canlet.2019.11.005. Epub 2019 Nov 6.
3
Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.非 KMT2A 重排婴儿急性淋巴细胞白血病中隐匿性的 ACIN1-NUTM1 融合。
Genes Chromosomes Cancer. 2020 Feb;59(2):125-130. doi: 10.1002/gcc.22808. Epub 2019 Oct 4.
4
Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.急性白血病伴 KMT2A/MLLT10 融合:单个基因组学实验室的 10 年经验。
Genes Chromosomes Cancer. 2019 Aug;58(8):567-577. doi: 10.1002/gcc.22741. Epub 2019 Mar 19.
5
Gene in Childhood B-cell Precursor Acute Lymphoblastic Leukemia: Interplay between Genetic Susceptibility and Somatic Abnormalities.儿童 B 细胞前体急性淋巴细胞白血病中的基因:遗传易感性与体细胞异常之间的相互作用。
Cancer Prev Res (Phila). 2017 Dec;10(12):738-744. doi: 10.1158/1940-6207.CAPR-17-0121. Epub 2017 Sep 25.
6
IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.IKZF1 缺失与日本儿童 B 细胞前体急性淋巴细胞白血病的不良预后相关。
Cancer Med. 2013 Jun;2(3):412-9. doi: 10.1002/cam4.87. Epub 2013 May 9.
7
Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.Ikaros 缺失与 BCR-ABL 阴性儿童急性淋巴细胞白血病的独特基因表达特征相关,但不会导致内在的化疗耐药性。
Pediatr Blood Cancer. 2014 Oct;61(10):1779-85. doi: 10.1002/pbc.25119. Epub 2014 Jun 29.
8
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.BCR-ABL1阳性急性淋巴细胞白血病中IKZF1(伊卡洛斯)缺失与无病生存期短及高累积复发率相关:一项GIMEMA AL WP报告
J Clin Oncol. 2009 Nov 1;27(31):5202-7. doi: 10.1200/JCO.2008.21.6408. Epub 2009 Sep 21.
9
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.在 AIEOP-BFM ALL 2017 临床试验中,对急性淋巴细胞白血病进行 RNA 测序和 array CGH 的实施。
Ann Hematol. 2020 Apr;99(4):809-818. doi: 10.1007/s00277-020-03953-3. Epub 2020 Feb 20.
10
Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.治疗反应差与伴有 KMT2A 重排的儿童 B 细胞急性淋巴细胞白血病的不良预后相关。
BMC Cancer. 2022 Aug 6;22(1):859. doi: 10.1186/s12885-022-09804-w.

本文引用的文献

1
Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance.KMT2A/MLL重排急性白血病中的酪氨酸激酶作为克服癌症耐药性的潜在治疗靶点。
Cancer Drug Resist. 2022 Oct 9;5(4):902-916. doi: 10.20517/cdr.2022.78. eCollection 2022.
2
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.阿扎胞苷和 venetoclax 治疗婴儿 KMT2A 重排急性淋巴细胞白血病的临床前疗效显示出新的治疗策略。
Leukemia. 2023 Jan;37(1):61-71. doi: 10.1038/s41375-022-01746-3. Epub 2022 Nov 15.
3
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
FLT3 抑制剂 lestaurtinib 联合化疗治疗新诊断的 KMT2A 重排婴儿急性淋巴细胞白血病:儿童肿瘤学组试验 AALL0631。
Leukemia. 2021 May;35(5):1279-1290. doi: 10.1038/s41375-021-01177-6. Epub 2021 Feb 23.
4
Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.维奈托克和地塞米松与奥英妥珠单抗诱导的B系急性淋巴细胞白血病DNA损伤信号协同作用。
Blood. 2021 May 13;137(19):2657-2661. doi: 10.1182/blood.2020008544.
5
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.恩特索利替尼与化疗联合治疗婴幼儿急性淋巴细胞白血病患者来源异种移植模型的疗效。
Haematologica. 2021 Apr 1;106(4):1067-1078. doi: 10.3324/haematol.2019.241729.
6
Blinatumomab for infant acute lymphoblastic leukemia.博纳吐单抗用于婴儿急性淋巴细胞白血病。
Blood. 2020 Apr 23;135(17):1501-1504. doi: 10.1182/blood.2019004008.
7
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.KMT2A 重排急性淋巴细胞白血病:揭示这种高危疾病的基因组复杂性和异质性。
Cancer Lett. 2020 Jan 28;469:410-418. doi: 10.1016/j.canlet.2019.11.005. Epub 2019 Nov 6.
8
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.治疗诱导的突变驱动复发急性淋巴细胞白血病的基因组景观。
Blood. 2020 Jan 2;135(1):41-55. doi: 10.1182/blood.2019002220.
9
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.《国际多中心 III 期随机研究:婴儿急性淋巴细胞白血病采用 Interfant-06 方案治疗的结局》
J Clin Oncol. 2019 Sep 1;37(25):2246-2256. doi: 10.1200/JCO.19.00261. Epub 2019 Jul 8.
10
Identification and Characterization of Novel Fusion Genes with Potential Clinical Applications in Mexican Children with Acute Lymphoblastic Leukemia.鉴定和描述具有潜在临床应用价值的新型融合基因在墨西哥儿童急性淋巴细胞白血病中的作用。
Int J Mol Sci. 2019 May 15;20(10):2394. doi: 10.3390/ijms20102394.